Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up.

D. E. Hallahan, M. L. Griem, S. F. Griem, M. Medenica, K. Soltani, A. L. Lorincz, J. M. Baron

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Twenty-one patients with tumor stage mycosis fungoides (MF) with or without lymph node (LN) involvement, were treated with total skin electron beam irradiation (TSEB) followed by six monthly cycles of systemic chemotherapy (CT) of either mechlorethamine (HN2) or cyclophosphamide (CTX) with vincristine (VCR), procarbazine, and prednisone (PRD) (COPP or MOPP). All patients had complete clearing of the skin after TSEB. However, while receiving chemotherapy, two patients developed visceral involvement and eight patients relapsed with limited cutaneous plaques (LCP). The median duration of remission was 12 months from the completion of TSEB, and all patients relapsed with cutaneous plaques within 25 months. Complete remission was again achieved using additional electron irradiation and maintenance therapy in all but one patient. Multiple cutaneous recurrences occurred in all patients. Median survival from the initiation of TSEB is 6 years. Five patients are living beyond 8 years (four off treatment without disease for 1 to 7 years). LN involvement did not influence initial response or survival. Combined modality therapy for tumor stage MF using TSEB followed by systemic CT and subsequent maintenance therapy may lead eventually to prolonged disease-free survival (DFS) in selected patients.

Original languageEnglish
Pages (from-to)1177-1183
Number of pages7
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume6
Issue number7
DOIs
StatePublished - Jul 1988

Fingerprint

Dive into the research topics of 'Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up.'. Together they form a unique fingerprint.

Cite this